Аннотация
На сегодняшний день фибрилляция предсердий стала одной из важнейших проблем общественного
здравоохранения и одной из основных причин увеличения расходов на систему здравоохранения.
Фибрилляция предсердий ассоциируется с такими социально-экономическими проблемами, как стойкая
утрата трудоспособности, когнитивные нарушения, частые госпитализации. Одним из грозных осложнений данного вида аритмии является ишемический инсульт, приводящий к инвалидизации и смерти
пациента. При фибрилляции предсердий риск развития инсульта и тромбоэмболических осложнений возрастает в пять раз, сердечной недостаточности – в три раза, а риск деменции и смерти увеличивается вдвое. Мероприятия по профилактике пароксизмов фибрилляции предсердий, включающие антиаритмическую терапию и катетерную аблацию, недостаточно эффективны. Объясняется это неполным
пониманием патогенетических механизмов, лежащих в основе возникновения аритмии. В данной статье продемонстрировано прогностическое значение нейрогуморальных маркеров, маркеров воспаления, фиброза, повреждения миокарда и эндотелиальной дисфункции в развитии фибрилляции предсердий и ее осложнений.
Литература
1. Chugh S.S., Havmoeller R., Narayanan K. et al.
Worldwide epidemiology of atrial fibrillation: a
Global Burden of Disease 2010 Study. Circulation.
2014; 129 (8): 837–47.
2. Zoni-Berisso M., Lercari F., Carazza T. et al.
Epidemiology of atrial fibrillation: European perspective.
Clin. Epidemiol. 2014; 6: 213–20.
3. Бокерия Л.А., Шенгелия Л.Д. Механизмы фиб-
рилляции предсердий: от идей и гипотез к эффективному пониманию проблемы. Анналы
аритмологии. 2014; 11 (1): 5–9. DOI:
10.15275/annaritmol.2014.1.1. / Bockeria L.A.,
Shengelia L.D. Mechanisms of atrial fibrillation:
from ideas and hypotheses to effective understanding
of the problem. Annaly Aritmologii. 2014; 11 (1):
5–9. DOI: 10.15275/annaritmol.2014.1.1 (in
Russian).
4. Ellinor P.T., Low A.F., Patton K.K. et al. Discordant
atrial natriuretic peptide and brain natriuretic peptide
levels in atrial fibrillation. J. Am. Coll. Cardiol.
2005; 45: 82–6.
5. Hijazi Z., Oldgren J., Andersson U. et al. Cardiac
biomarkers are associated with an increased risk of
stroke and death in patients with atrial fibrillation: a
Randomized Evaluation of Long-term
Anticoagulation Therapy (RE-LY) substudy.
Circulation. 2012; 125 (13): 1605–16.
6. Sinner M.F., Stepas K.A., Moser C.B. et al. B-type
natriuretic peptide and C-reactive protein in the
prediction of atrial fibrillation risk: the CHARGEAF
Consortium of community-based cohort studies.
Europace. 2014; 16 (10): 1426–33.
7. Danicek V., Theodorovich N., Bar-Chaim S. et al.
Sinus rhythm restoration after atrial fibrillation: the
clinical value of N-terminal pro-BNP measurements.
Pacing Clin. Electrophysiol. 2008; 31 (8):
955–60.
8. Beck-da-Silva L., de Bold A., Fraser M. et al. Brain
natriuretic peptide predicts successful cardioversion
in patients with atrial fibrillation and maintenance
of sinus rhythm. Can. J. Cardiol. 2004; 20 (12):
1245–8.
9. Wożakowska-Kapłon B. Effect of sinus rhythm
restoration on plasma brain natriuretic peptide in
patients with atrial fibrillation. Am. J. Cardiol. 2004;
93: 1555–8.
10. Tang Y., Yang H., Qiu J. Relationship between brain
natriuretic peptide and recurrence of atrial fibrillation
after successful electrical cardioversion: a
meta-analysis. J. Int. Med. Res. 2011; 39 (5):
1618–24.
11. Solheim E., Off M.K., Hoff P.I. et al. N-terminal
pro-B-type natriuretic peptide level at long-term
follow-up after atrial fibrillation ablation: a marker
of reverse atrial remodelling and successful ablation.
J. Interv. Card. Electrophysiol. 2012; 34 (2): 129–36.
12. Arana-Rueda E., Pedrote A., García-Riesco L. et al.
Clinical value of N-terminal pro-B-type natriuretic
peptide measurement in the follow up of pulmonary
vein ablation. Med. Clin. (Barc.) 2015.
13. Tzikas S., Keller T., Wild PS. et al. Midregional proatrial
natriuretic peptide in the general population/Insights
from the Gutenberg Health Study.
Clin. Chem. Lab. Med. 2013; 51 (5): 1125–33.
14. Latini R., Masson S., Pirelli S. et al. Circulating cardiovascular
biomarkers in recurrent atrial fibrillation:
data from the GISSI-atrial fibrillation trial.
J. Intern. Med. 2011; 269 (2): 160–71.
15. Wozakowska-Kaplon B., Opolski G. Atrial natriuretic
peptide level aftІer cardioversion of chronic atrial
fibrillation. Int. J. Cardiol. 2002; 83 (2): 159–65.
16. Meune C., Vermillet A., Wahbi K. et al. Mid-regional
pro atrial natriuretic peptide allows the accurate
identification of patients with atrial fibrillation of
short time of onset: a pilot study. Clin. Biochem.
2011; 44 (16): 1315–9.
17. Hijazi Z., Wallentin L., Siegbahn A. et al. High-sensitivity
troponin T and risk stratification in patients
with atrial fibrillation during treatment with apixaban
or warfarin. J. Am. Coll. Cardiol. 2014; 7–14; 63
(1): 52–61.
18. Hijazi Z., Siegbahn A., Andersson U. et al.
Comparison of cardiac troponins I and T measured
with high-sensitivity methods for evaluation of
prognosis in atrial fibrillation: an ARISTOTLE substudy.
Clin. Chem. 2015; 61 (2): 368–78.
19. Latini R., Masson S., Pirelli S. et al. Circulating cardiovascular
biomarkers in recurrent atrial fibrillation:
data from the GISSI-atrial fibrillation trial.
J. Intern. Med. 2011; 269 (2): 160–71.
20. Ulimoen S.R., Enqer S. Norseth J. et al. Improved
rate control reduces cardiac troponin T levels in
permanent atrial fibrillation. Clin. Cardiol. 2014; 37
(7): 422–7.
21. Wu N., Chen X., Cai T. et al. Association of inflammatory
and hemostatic markers with stroke and
thromboembolic events in atrial fibrillation: A systematic
review and meta-analysis. Can. J. Cardiol.
2015; 31 (3): 278–86.
22. Christersson C., Wallentin L., Andersson U. et al. Ddimer
and risk of thromboembolic and bleeding
events in patients with atrial fibrillation – observations
from the ARISTOTLE trial. J. Thromb.
Haemost. 2014; 12 (9): 1401–12.
23. Oral H., Chugh A., Ozaydin M. et al. Risk of thromboembolic
events after percutaneous left atrial
radiofrequency ablation of atrial fibrillation.
Circulation. 2006; 114: 759–65.
24. Lim H.S., Schultz C., Dang J. et al. Time course of
inflammation, myocardial injury, and prothrombotic
response after radiofrequency catheter ablation
for atrial fibrillation. Circ. Arrhythm. Electrophysiol.
2014; 7 (1): 83–9.
25. Freestone B., Chong A.Y., Nuttall S. et al. Soluble Eselectin,
von Willebrand factor, soluble thrombomodulin,
and total body nitrate/nitrite product as
indices of endothelial damage/dysfunction in
paroxysmal, persistent, and permanent atrial fibrillation.
Chest. 2007; 132 (4): 1253–58.
26. Scridon A., Girerd N., Rugeri L. et al. Progressive
endothelial damage revealed by multilevel von Willebrand
factor plasma concentrations in atrial fibrillation
patients. Europace. 2013; 15 (11): 1562–6.
27. Roldán V., Marín F., Mui~na B. et al. Plasma von
Willebrand factor levels are an independent risk factor
for adverse events including mortality and major
bleeding in anticoagulated atrial fibrillation
patients. J. Am. Coll. Cardiol. 2011. 21; 57 (25):
2496–504.
28. Girerd N., Scridon A., Bessi`ere F. et al. Periatrial epicardial
fat is associated with markers of endothelial
dysfunction in patients with atrial fibrillation. PLoS
One. 2013; 8 (10): e77167.
29. Yongjun Q., Huanzhang S., Wenxia Z. et al. From
changes in local RAAS to structural remodeling of
the left atrium: A beautiful cycle in atrial fibrillation.
Herz. 2015; 40 (3): 514–20.
30. Goette A., Staack T., Rocken C., Arndt M., Geller
J.C., Huth C. Increased expression of extracellular
signal-regulated kinase and angiotensin-converting
enzyme in human atria during atrial fibrillation.
J. Am. Coll. Cardiol. 2000; 35 (6): 1669–77.
31. Schneider M.P., Hua T.A., Böhm M. et al.
Prevention of atrial fibrillation by ReninAngiotensin
system inhibition a meta-analysis.
J. Am. Coll. Cardiol. 2010; 55 (21): 2299–307.
32. Huang G., Xu J.B., Liu J.X. et al. Angiotensin-converting
enzyme inhibitors and angiotensin receptor
blockers decrease the incidence of atrial fibrillation:
a meta-analysis. Eur. J. Clin. Invest. 2011; 41 (7):
719–33.
33. Reil J.C., Hohl M., Selejan S. et al. Aldosterone promotes
atrial fibrillation. Eur. Heart J. 2012; 33 (16):
2098–108.
34. Zhao J., Li J., Li W. et al. Effects of spironolactone
on atrial structural remodelling in a canine model of
atrial fibrillation produced by prolonged atrial pacing.
Br. J. Pharmacol. 2010; 159 (8): 1584–94.
35. Swedberg K., Zannad F., McMurray J.J. et al.
Eplerenone and atrial fibrillation in mild systolic
heart failure: results from the EMPHASIS-HF
(Eplerenone in Mild Patients Hospitalization And
SurvIval Study in Heart Failure) study. J. Am. Coll.
Cardiol. 2012; 59 (18): 1598–603.
36. Wozakowska-Kaplon B., Bartkowiak R., Janiszewska
G. A decrease in serum aldosterone level is
associated with maintenance of sinus rhythm after
successful cardioversion of atrial fibrillation. Pacing
Clin. Electrophysiol. 2010; 33 (5): 561–5.
37. Ogimoto A., Hamada M., Nakura J. et al. Relation
between angiotensin-converting enzyme II genotype
and atrial fibrillation in Japanese patients with
hypertrophic cardiomyopathy. J. Hum. Genet. 2002;
47 (4): 184–9.
38. Xiao P., Ling Z., Woo K. et al. Renin-angiotensin
system-related gene polymorphisms are associated
with risk of atrial fibrillation. Am. Heart J. 2010; 160
(3): 496–505.
39. Ueberham L., Bollmann A., Shoemaker M.B. et al.
Genetic ACE I/D polymorphism and recurrence of
atrial fibrillation after catheter ablation. Circ.
Arrhythm. Electrophysiol. 2013; 6 (4): 732–7.
40. Liu T., Korantzopoulos P., Xu G. et al. Association
between angiotensin-converting enzyme insertion/deletion
gene polymorphism and atrial fibrillation:
a meta-analysis. Europace. 2011; 13 (3):
346–54.
41. Yamashita T., Sekiguchi A., Iwasaki Y.K. et al.
Recruitment of immune cells across atrial endocardium
in human atrial fibrillation. Circ. J. 2010;
74 (2): 262–70.
42. Casaclang-Verzosa G., Barnes ME., Blume G. et al.
C-reactive protein, left atrial volume, and atrial fibrillation:
a prospective study in high-risk elderly.
Echocardiography. 2010; 27 (4): 394–9.
43. Wu N., Xu B., Xiang Y. Association of inflammatory
factors with occurrence and recurrence of atrial fibrillation:
a meta-analysis. Int. J. Cardiol. 2013; 169
(1): 62–72.
44. Hermida J., Lopez FL., Montes R.et al. Usefulness of
high-sensitivity C-reactive protein to predict mortality
in patients with atrial fibrillation (from the
Atherosclerosis Risk In Communities [ARIC]
Study). Am. J. Cardiol. 2012; 109 (1): 95–9.
45. Yang Q., Qi X., Li Y. The preventive effect of atorvastatin
on atrial fibrillation: a meta-analysis of randomized
controlled trials. BMC Cardiovasc. Disord.
2014; 14: 99.
46. Platonov P., Ekesbo R., Hansson A. et al. Permanent
atrial fibrillation in patients without structural heart
disease is not associated with signs of infection by
Chlamydia pneumoniae and Helicobacter pylori.
Acta Cardiol. 2008; 63 (4): 479–84.
47. Kiryu M., Niwano S., Niwano H. et al. Angiotensin
II-mediated up-regulation of connective tissue
growth factor promotes atrial tissue fibrosis in the
canine atrial fibrillation model. Europace. 2012; 14
(8): 1206–14.
48. Rosenberg M.A., Maziarz M., Tan A.Y. et al.
Circulating fibrosis biomarkers and risk of atrial fibrillation:
The Cardiovascular Health Study (CHS).
Am. Heart J. 2014; 167 (5): 723–8.
49. Mukherjee R., Akar J.G., Wharton J.M. et al. Plasma
profiles of matrix metalloproteinases and tissue
inhibitors of the metalloproteinases predict recurrence
of atrial fibrillation following cardioversion.
J. Cardiovasc. Transl. Res. 2013; 6 (4): 528–35.
50. Sonmez O., Ertem F.U., Vatankulu M.A. et al. Novel
fibro-inflammation markers in assessing left atrial
remodeling in non-valvular atrial fibrillation. Med.
Sci. Monit. 2014; 20: 463–70.
Об авторах
Жолбаева Айгерим Замирбековна, аспирант;
Табина Анастасия Евгеньевна, аспирант;
Голухова Елена Зеликовна, доктор мед. наук, профессор, чл.-корр. РАН, заведующий отделением
